Tier C · Early / limited human evidence
Ipamorelin
A selective GH secretagogue that reached human trials but never established a standard therapeutic role.
Why researchers care
Potential human relevance
- Stimulates growth hormone release with relative selectivity in preclinical pharmacology
- Advanced into a randomized phase 2 human trial for postoperative ileus
- Provides a model for targeted ghrelin-receptor drug development
What the human evidence says
Evidence, not extrapolation
Human clinical development exists, but a proven general health, recovery or body-composition benefit has not been established.
How to think about it
The Yooper Peptides take
The internet often discusses ipamorelin as if its GH-release mechanism automatically proves outcomes. The clinical evidence does not support that leap.
Primary / authoritative reading